8-K/A: Verano Holdings Revises 2023 Financials After Identifying $9 Million Fixed Asset Impairment

Verano Holdings Corp. has reissued its fourth quarter and full year 2023 financial results to reflect a $9 million fixed asset impairment related to its Massachusetts cultivation facility.

Summary

• Verano Holdings Corp. announced revised financial results for the fourth quarter and full year ended December 31, 2023, due to a $9 million fixed asset impairment.
• The impairment resulted in a $5 million reduction in net income, net of tax effects, and a $9 million reduction in the Property, Plant and Equipment balance.
• The company's full year revenue reached $938 million, a 7% increase year-over-year, with a gross profit of $475 million or 51% of revenue.
• Net loss for the full year was $(117) million, or (13)% of revenue, an improvement from the previous year's loss of $(269) million.
• Adjusted EBITDA for the full year was $305 million, or 32% of revenue, and free cash flow was $73 million.
• For the fourth quarter, revenue was $237 million, a 5% increase year-over-year, with a net loss of $(77) million, or (33)% of revenue.
• The company's net cash provided by operating activities for the full year was $110 million, a 16% increase year-over-year.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to the restatement of financials and the impairment charge, offset by positive revenue growth and free cash flow generation. The forward guidance is also negative.

Positives

• Full year revenue increased by 7% year-over-year to $938 million.
• Gross profit for the full year was $475 million, up from $423 million in the previous year.
• Net loss for the full year improved significantly to $(117) million from $(269) million in the previous year.
• Free cash flow for the full year was $73 million, a substantial improvement from $(25) million in the previous year.
• Net cash provided by operating activities increased to $110 million for the full year, up from $94 million in the previous year.
• SG&A expenses decreased to 35% of revenue for the full year, down from 41% in the previous year.
• Fourth quarter revenue increased by 5% year-over-year to $237 million.
• Net cash provided by operating activities for the fourth quarter increased to $32 million from $29 million in the previous year.

Negatives

• A $9 million fixed asset impairment was identified, reducing net income by $5 million, net of tax effects.
• The company reported a net loss of $(117) million for the full year and $(77) million for the fourth quarter.
• The company has a working capital deficit of $(18) million.
• The company's total debt, net of issuance costs, is $446 million.
• The company is guiding for a 5-7% revenue decline in the first quarter of 2024 compared to the prior year period.

Risks

• The company identified a fixed asset impairment, indicating potential issues with asset valuation.
• The company is guiding for a revenue decline in the first quarter of 2024, suggesting potential challenges in maintaining growth.
• The company has a working capital deficit, which could impact its short-term financial flexibility.
• The company has a significant amount of debt, which could pose a risk if not managed effectively.
• The cannabis industry is subject to regulatory changes, which could impact the company's operations and financial performance.

Future Outlook

The company issued first quarter 2024 revenue guidance of a 5-7% decline versus the prior year period due to the normalization of dispensary counts in New Jersey.

Management Comments

• George Archos, Verano Founder and Chief Executive Officer, stated he is incredibly proud of the company's performance in 2023.
• He believes 2024 has the potential to be a game-changing year for the industry and that Verano is well positioned to capitalize on growth opportunities.
• He also noted the potential impact of adult use legalization in Ohio, Florida, and Pennsylvania, as well as the possibility of federal rescheduling.

Industry Context

The announcement comes amid growing anticipation for regulatory changes in the cannabis industry, including potential federal rescheduling and the expansion of adult-use markets in several states. Verano's performance is being closely watched as a bellwether for the broader cannabis sector.

Comparison to Industry Standards

• Verano's revenue growth of 7% year-over-year is moderate compared to some other multi-state operators in the cannabis industry, some of which have seen double-digit growth.
• The company's adjusted EBITDA margin of 32% is within the range of industry averages for established cannabis companies.
• The impairment charge is not uncommon in the cannabis industry, as companies often adjust asset values based on market conditions and regulatory changes.
• Compared to companies like Curaleaf and Trulieve, Verano's revenue is lower, but its focus on profitability and cash flow is a key differentiator.
• The company's free cash flow generation is a positive sign, as many cannabis companies struggle with cash flow management.

Legal Proceedings

• The company announced its participation in a coalition of industry stakeholders as a plaintiff challenging the legality of the federal government's intervention in legal intrastate cannabis commerce.

Stakeholder Impact

• Shareholders may be concerned about the restatement of financials and the impairment charge.
• Employees may be impacted by any changes in the company's strategy or operations.
• Customers may benefit from the company's continued expansion and product development.
• Suppliers may be impacted by any changes in the company's purchasing patterns.
• Creditors may be concerned about the company's debt levels and working capital deficit.

Next Steps

• The company will continue to monitor its asset valuations and make adjustments as necessary.
• Verano will focus on expanding its retail footprint and capitalizing on growth opportunities in new and existing markets.
• The company will continue to advocate for regulatory changes that support the cannabis industry.

Key Dates

Keywords

cannabis, financial results, impairment, revenue, EBITDA, net loss, free cash flow, multi-state operator, fixed assets, operating activities